Dosing and uses of Patanase (olopatadine intranasal)
Adult dosage forms and strengths
nasal spray
- 6% (665mcg/100 microliters spray)
Seasonal Allergic Rhinitis
2 sprays per nostril q12hr
Administration
Prime nasal spray before initial use and when not in use for >7 days
Pediatric dosage forms and strengths
nasal spray
- 6% (665mcg/100 microliters spray)
Seasonal Allergic Rhinitis
<6 years: Safety and efficacy not established
6-12 years: 1 spray per nostril q12hr
>12 years: 2 sprays per nostril q12hr
Administration
Prime nasal spray before initial use and when not in use for >7 days
Patanase (olopatadine intranasal) adverse (side) effects
>10%
Bitter taste (12.8%; 1% pediatric)
Respiratory epistaxis (3-25%)
1-10%
Headache (4.4%)
Depression (2%)
Fatigue (1%)
Somnolence (1%)
Weight gain (1%)
Epistaxis (3.2%; 5.7% pediatric)
Upper respiratory tract infection (2.6% pediatric)
Pharyngolaryngeal pain (2.2%)
Postnasal drip (1.5%)
Cough (1.4%)
Urinary tract infection (1.2%)
Upper respiratory tract infection in children (3%)
<1%
CPK elevation
Dry mouth
Anosmia
Hyposmia
Nasopharyngitis
Throat irritation
Influenza
Warnings
Contraindications
Hypersensitivity
Cautions
May cause epistaxis, nasal ulceration, or nasal septal perforation
Avoid with nasal disease other than allergic rhinitis
May impair mental/physical abilities required for hazardous tasks (eg, driving, operating machinery)
Avoid concurrent use of alcohol or other CNS depressants (possible additive sedation)
Pregnancy and lactation
Pregnancy category: C
Lactation: Unknown whether distributed in breast milk, caution advised
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Patanase (olopatadine intranasal)
Mechanism of action
Antihistamine (H1 antagonist); inhibits release of histamine from mast cells.
Pharmacokinetics
Half-Life: 8-12 hr
Onset of action: 30 min (seasonal allergy)
Absorption: Systemic 57%
Bioavailability 57%
Peak Plasma Time: 0.25-2 hr
Peak Plasma Concentration: 23.3 ng/mL
Protein Bound: 55% (predominantly albumin)
Metabolites: N-desmethyl olopatadine; olopatadine N-oxide
Metabolism: Liver; not extensive
Excretion: Urine (60-70% unchanged); feces (17%)
